Searching News Database: phosphodiesterase
HSMN NewsFeed - 8 Aug 2018
United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
HSMN NewsFeed - 20 Nov 2017
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
HSMN NewsFeed - 23 Oct 2017
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
HSMN NewsFeed - 29 Sep 2017
Dermavant Sciences Appoints Vince Ippolito as President and Chief Operating Officer
Dermavant Sciences Appoints Vince Ippolito as President and Chief Operating Officer
HSMN NewsFeed - 30 Sep 2013
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
HSMN NewsFeed - 24 Aug 2011
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
HSMN NewsFeed - 25 May 2011
VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
HSMN NewsFeed - 26 Apr 2010
Nycomed and Merck & Co., Inc., Announce Commercialization Agreements For Daxas(R) in Europe and Canada
Nycomed and Merck & Co., Inc., Announce Commercialization Agreements For Daxas(R) in Europe and Canada
HSMN NewsFeed - 26 May 2009
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
HSMN NewsFeed - 17 Nov 2008
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
HSMN NewsFeed - 30 Jun 2008
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
HSMN NewsFeed - 2 Jun 2008
Rexahn Pharmaceuticals Initiates Phase II Trial for Zoraxel(TM) to Treat Erectile Dysfunction
Rexahn Pharmaceuticals Initiates Phase II Trial for Zoraxel(TM) to Treat Erectile Dysfunction
HSMN NewsFeed - 1 Feb 2008
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
HSMN NewsFeed - 1 Nov 2007
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
HSMN NewsFeed - 27 Mar 2007
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
Additional items found! 46
Members Archive contains
46 additional stories matching:
phosphodiesterase
(Password required)
phosphodiesterase
(Password required)